small molecule

BONDLIDO

LIDOCAINE

Loss of exclusivitySeptember 2028FDA regulatory exclusivity expiry

CompanyMEDRx →See this company's full patent-cliff portfolio

Drug detail

Brand name	BONDLIDO
Active ingredient	LIDOCAINE
Strength	10%
Dosage form	SYSTEM
Route	TOPICAL
Modality	Small molecule
FDA approval	September 2025
Marketing status	RX

Regulatory exclusivity

Code	Expires
NP	September 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.